Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) EVP Ourania Tatsis Sells 244 Shares

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) EVP Ourania Tatsis sold 244 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $455.06, for a total value of $111,034.64. Following the completion of the transaction, the executive vice president now owns 67,695 shares in the company, valued at approximately $30,805,286.70. This represents a 0.36 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Ourania Tatsis also recently made the following trade(s):

• On Tuesday, February 11th, Ourania Tatsis sold 310 shares of Vertex Pharmaceuticals stock. The stock was sold at an average price of $459.83, for a total transaction of $142,547.30.

Vertex Pharmaceuticals Stock Up 0.8 %

VRTX opened at $484.24 on Friday. Vertex Pharmaceuticals Incorporated has a 12 month low of $377.85 and a 12 month high of $519.88. The company has a quick ratio of 2.35, a current ratio of 2.69 and a debt-to-equity ratio of 0.01. The company has a 50 day moving average of $436.05 and a 200 day moving average of $460.70.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 EPS for the quarter, missing analysts’ consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. Equities analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Institutional Investors Weigh In On Vertex Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the business. Northwest Investment Counselors LLC bought a new stake in Vertex Pharmaceuticals during the third quarter worth about $25,000. Dunhill Financial LLC increased its holdings in Vertex Pharmaceuticals by 70.6% during the 3rd quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 24 shares during the period. Highline Wealth Partners LLC bought a new position in shares of Vertex Pharmaceuticals during the third quarter valued at approximately $27,000. Legacy Investment Solutions LLC purchased a new stake in shares of Vertex Pharmaceuticals in the 3rd quarter worth about $33,000. Finally, Brown Lisle Cummings Inc. purchased a new stake in Vertex Pharmaceuticals in the fourth quarter worth about $30,000. Institutional investors own 90.96% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on VRTX. Scotiabank upped their target price on shares of Vertex Pharmaceuticals from $433.00 to $450.00 and gave the stock a “sector perform” rating in a report on Tuesday, February 11th. UBS Group raised their target price on Vertex Pharmaceuticals from $562.00 to $586.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. BMO Capital Markets cut their target price on Vertex Pharmaceuticals from $566.00 to $520.00 and set an “outperform” rating on the stock in a research report on Friday, December 20th. Jefferies Financial Group raised Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and increased their price target for the company from $500.00 to $550.00 in a research report on Monday, December 9th. Finally, Royal Bank of Canada lifted their price objective on shares of Vertex Pharmaceuticals from $407.00 to $408.00 and gave the stock a “sector perform” rating in a report on Thursday. Eleven research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $505.61.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.